Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGR4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGR4 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native glycosylation. |
View LGR4 Products |
| Gene Delivery | LGR4 Lentivirus Premade Particles Full-length human LGR4 ORF for stable cell line construction and GPCR conformation preservation. |
View LGR4 Products |
| Benchmark Ab | Anti-LGR4 Recombinant Antibody Recombinant positive control derived from clinical-stage sequences. |
View LGR4 Products |
| Validator | LGR4 siRNA Set Target-specific gene knockdown validation. |
View LGR4 Products |
| Related Target A | RSPO1 Natural ligand of LGR4; essential for Wnt pathway potentiation and ligand-blocking assays. |
View RSPO1 Products |
| Related Target B | LGR5 Homologous receptor; crucial for off-target counter-screening and selectivity profiling. |
View LGR5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Loss | Lentivirus-driven full-length LGR4 expression ensures stable integration and native 7-TM folding in host cell lines. |
| Ligand-Binding Assay Interference | HEK293-expressed LGR4 ECD-Fc features correct mammalian glycosylation patterns, preventing false negatives in RSPO binding studies. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as recombinant positive controls. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live LGR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGR4 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to antibody-drug conjugates (ADCs) and bispecific constructs. As first-generation Wnt-pathway modulators reach the clinic, the next wave of R&D is targeting selective LGR4 internalization and tumor-specific microenvironment activation to mitigate systemic toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Oncology Biotechs | Colorectal Cancer, Gastric Cancer | Internalization Assay (Need high-purity LGR4 ECD-Fc and stable cells) |
| Bispecific Antibody | Immunotherapy Pioneers | Solid Tumors, Stem Cell Disorders | Affinity Validation (Need Cross-reactive LGR4 and LGR5 proteins) |
| Ligand Blockers | Translational Research Labs | Osteoporosis, Inflammatory Diseases | RSPO Binding Competition (Need biologically relevant RSPO1/3 proteins) |